Aflibercept Injection for Proliferative Diabetic Retinopathy

Status Completed

Clinical Trial Summary

To evaluate the ocular and systemic safety of intravitreal aflibercept injection in patients undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy.

Clinical Trial Description

Patients who need Pars Plana Vitrectomy surgery, and agree to participate in this study will receive an injection of 2.0mg aflibercept 4 to 6 days before Vitrectomy surgery. Half of these patients will be randomized to receive another injection of 2.0mg aflibercept immediately after their surgery. Postoperative patient visits in this study will be at 1 day, and at weeks 1, 4, 16 and 24, and at any other times as deemed necessary by the Investigator. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01805297
Study type	Interventional
Source	University of Oklahoma
Contact
Status	Completed
Phase	Phase 2
Start date	March 2013
Completion date	November 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00411970` - 20- Versus 23- Gauge System for Pars Plana Vitrectomy	Phase 4
Completed	`NCT00155454` - Intravitreal Long Acting Gas in the Prevention of Early Postoperative Vitreous Hemorrhage in Diabetic Vitrectomy	N/A
Completed	`NCT00000154` - Diabetic Retinopathy Vitrectomy Study (DRVS)	Phase 3
Recruiting	`NCT05514925` - Cryoapplication Versus Anti-VEGF Before Diabetic Vitrectomy	Phase 4
Completed	`NCT02858076` - Anti-VEGF vs. Prompt Vitrectomy for VH From PDR	Phase 2/Phase 3
Completed	`NCT00596297` - Preoperative Bevacizumab for Vitreous Hemorrhage	Phase 1/Phase 2
Completed	`NCT00198510` - Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage	Phase 3
Completed	`NCT01854593` - Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy	Phase 4
Completed	`NCT04859556` - Performance, Safety and Efficiency Comparison Between 10,000 and 5,000 Cuts Per Minute Vitrectomy Using a 25G Cutter - A Prospective Randomized Controlled Study	N/A
Recruiting	`NCT01824043` - Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage	Phase 4
Completed	`NCT06383754` - Clareon Intraocular Lens Stability in Vitrectomy Patients: CLOVE Study	N/A
Not yet recruiting	`NCT04346095` - Oral Sedation in Vitreoretinal Surgery	Phase 4
Completed	`NCT00996437` - Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)	Phase 2/Phase 3
Completed	`NCT00745498` - Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy	N/A
Completed	`NCT00198497` - Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage	Phase 3
Completed	`NCT00000162` - Branch Vein Occlusion Study	Phase 3
Completed	`NCT05710458` - Performance Comparison of the 25 Gauge 20,000cpm HYPERVIT Dual Blade vs. 10,000cpm ULTRAVIT Vitrectomy Cutter	N/A
Recruiting	`NCT05588037` - Combined Vitrectomy and Femtosecond Laser-assisted Cataract Surgery	N/A
Recruiting	`NCT05529589` - Comparison of Restoration in Vitreous Hemorrhage Patients With DME After or Not Removing Inner Limiting Membrane
Completed	`NCT04712786` - Refractive Changes Following Vitrectomy